{"id":"W4392820515","doi":"10.1136/jitc-2023-008409","title":"Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Oxaliplatin; Nivolumab; Oncology; Colorectal cancer; Clinical endpoint; Irinotecan; Randomized controlled trial; Progression-free survival; Phases of clinical research; Clinical trial; Cancer; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002926242,0.001284938,0.001614725,0.0003133803,0.0002997861,0.0009794052,0.0007684207,0.001315019,0.006291404],"category_scores_gemma":[0.002170159,0.0004721984,0.00158605,0.0002768502,0.0006617807,0.00071356,0.0004012568,0.001702854,0.0006483566],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001039281,"about_ca_system_score_gemma":0.001424436,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009210694,"about_ca_topic_score_gemma":0.002538258,"domain_scores_codex":[0.9993062,0.0004149902,0.00003775586,0.0001047326,0.00006186421,0.00007447276],"domain_scores_gemma":[0.9990543,0.0002291967,0.0002723018,0.00007147683,0.00006506564,0.0003077417],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9758654,0.004601022,0.001026065,0.0004357051,0.0009365884,0.00003132972,0.00002877406,0.0003960417,0.001930562,0.000101211,0.001932415,0.01271488],"study_design_scores_gemma":[0.9599425,0.03542575,0.002261891,0.00003176316,0.0005597337,0.00003523209,0.000007516168,0.0004417063,0.0003060817,0.00009101934,0.0008867953,0.00001004905],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9811556,0.005230504,0.0006696424,0.001176931,0.0004714008,0.005233735,0.003061792,0.000153081,0.002847276],"genre_scores_gemma":[0.9736223,0.002471094,0.003105623,0.002061387,0.0005981731,0.006594294,0.00643028,0.00004200564,0.005074846],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006291404,"threshold_uncertainty_score":0.02104688,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08274832123584072,"score_gpt":0.438821214677889,"score_spread":0.3560728934420483,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}